Skip to content
Tuesday, November 10, 2026
PrimeSuperPlace

Patients Stopping Slimming Medications Put On Pounds Far More Rapidly Compared to People Using Diet and Exercise

Image of pharmaceutical injection and scale
Obesity treatment involves long-term strategies.

New research suggests that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt traditional diet and exercise programs.

Published data in a major health publication points out that while overweight individuals frequently drop a large proportion of their total mass while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.

"Individuals buying such treatments must be cognizant of the risk of quick weight regain when the treatment is stopped," stated expert Dr. Susan Jebb.

That rate of regain implies a reversion to starting weight within about a year and a half.

Comparing Treatments

The study, which examined dozens of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills.

Scientists note that people who shed pounds through dieting typically see a slower creep back—approximately 100 grams monthly—after stopping.

Understanding the Fast Rebound

Nutrition scientists believe the mode of action of the jabs accounts for the accelerated weight return.

GLP-1 drugs imitate a natural hormone called GLP-1, which controls hunger.

"Artificially providing the hormone concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.

"Withdrawal of this medication results in hunger is no longer kept in check, making excessive eating much more probable."

An Ongoing Disease?

The NHS recommend the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.

A number of clinicians contend that, considering the significant potential of relapse, the therapy should be considered life-long.

This opinion is supported by pharmaceutical companies, who note that the results "emphasize the chronic character of excess weight," similar to managing diseases like hypertension.

Patient Testimonies

Individuals who have come off the jabs explain a powerful resurgence of cravings.

"It felt as if a switch activating and I was suddenly starving," recalled one woman.

This difficulty is exacerbated if users have not adopted permanent dietary or behavioural changes during therapy.

Significant Interest

Recent estimates show that a significant number of adults in the UK have tried these injections in the last 12 months, with interest being substantial.

  • Adoption is higher among females compared to males.
  • The middle-aged demographic shows the greatest level of interest.
  • A large proportion obtain the medications through private prescriptions rather than the NHS.

Ultimately, experts emphasize that while these medications are powerful agents for weight loss, they are not a permanent fix and lasting health benefits relies on ongoing behavioural support.

By

Jesus Chambers

Eleanor Frost is a seasoned writer and researcher with a passion for uncovering the best in lifestyle and tech.

PrimeSuperPlace

Type to search articles.